Tuesday, December 1, 2015   

1.3b yuan loss looms for investors in wealth products

Thursday, February 13, 2014

Two investment products worth nearly 1.3 billion yuan (HK$1.66 billion) that were distributed by China Construction Bank (0939) and Ping An Insurance (2318) are on the verge of default.

The first - a high-yield product that saw 289 million yuan raised from clients of China Construction Bank - was created by Jilin Province Trust and backed by a loan to coal firm Shanxi Lianmeng Energy.

"It matured on February 7, but CCB passed on an announcement from Jilin Trust saying `we currently can't be certain when [Lianmeng] funds will be returned," Shanghai Securities News reported.

Though the maturity date has already passed, thereby constituting a technical default, the Jilin trust appears to be working to recover investor funds.


"Restructuring isn't bankruptcy. As far as we know, there is no problem with the firm's assets. The firm is in negotiations with investors," the paper quoted an unnamed trust official as saying.

The second saw three funds backed by Beijing Roll- in Investment Management fail to repay investors after maturity. Capital plus interest on the product has reached one billion yuan, 21cbh.com reported.

Investors in Beijing claimed they bought the funds from Ping An Insurance. "[Ping An staff] promised to repay capital and interest. They claimed it is guaranteed by local governments and are deposited in Ping An Bank..." an investor said. But Ping An Insurance said it did not distribute such funds. LING WANG AND REUTERS

© 2015 The Standard, The Standard Newspapers Publishing Ltd.
Contact Us | About Us | Newsfeeds | Subscriptions | Print Ad. | Online Ad. | Street Pts


Home | Top News | Local | Business | China | ViewPoint | CityTalk | World | Sports | People | Central Station | Spree | Features

The Standard

Trademark and Copyright Notice: Copyright 2015, The Standard Newspaper Publishing Ltd., and its related entities. All rights reserved.  Use in whole or part of this site's content is prohibited.   Use of this Web site assumes acceptance of the
Terms of Use, Privacy Policy Statement and Copyright Policy.  Please also read our Ethics Statement.